Clinical trials review: crystal deposition diseases

Curr Rheumatol Rep. 1999 Dec;1(2):97-100. doi: 10.1007/s11926-999-0004-6.

Abstract

This review focuses on several recent clinically-related observations concerning Calcium Pyrophosphate Deposition Disease (CPPDD). Developments include new information on the epidemiology of idiopathic CPPDD in aging, on familial CPPDD, and on associated conditions that predispose to secondary CPPDD. Factors that may precipitate pseudogout, including the use of intra-articular hyaluronan and systemic G-CSF, are also discussed.

Publication types

  • Review

MeSH terms

  • Aged
  • Aging / metabolism*
  • Calcinosis / complications*
  • Calcinosis / diagnosis
  • Calcinosis / metabolism
  • Calcium Phosphates / metabolism*
  • Chondrocalcinosis / complications*
  • Chondrocalcinosis / diagnosis
  • Chondrocalcinosis / metabolism
  • Chondrocalcinosis / physiopathology
  • Chondrocalcinosis / therapy
  • Clinical Trials as Topic
  • Crystallization
  • Diphosphonates / metabolism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteoarthritis / complications*
  • Osteoarthritis / diagnosis
  • Osteoarthritis / metabolism
  • Osteoarthritis / therapy
  • Prognosis
  • Risk Assessment

Substances

  • Calcium Phosphates
  • Diphosphonates
  • alpha-tricalcium phosphate
  • tetracalcium phosphate
  • calcium phosphate, monobasic, anhydrous
  • calcium phosphate
  • calcium phosphate, dibasic, anhydrous